Contraceptive and menstrual cycle controlling drug having oncostatic properties

Abstract: The present invention relates to a drug for human use, having contraceptive and mestrual cycle controlling properties, comprising N-acetyl-2-bromo-5-metoxytryptamine (2-bromomelatonin) in a dose of 25-50 mg per day or N-acetyl-2-iodo-5-methoxytryptamine (2-iodomelatonin), in a dose of 20-40 mg per day, in association with a progestinic compound. The drug is administred for 23 days, by using an association of 2-iodomelatonin or 2-bromomelatonin and a progestinic compound, followed by 5 days in which only 2-iodomelatonin or 2-bromomelatonin is administred; the drug having oconstatic preventive and therapeutic proprieties, in mammary tumours and melanomas, characterized by the use of 2-iodomelatonin, or 2-bromomelatonin respectively with doses of 20-40 mg, 25-50 mg per day; the drug having moreover antikinestosic properties, and being characterized by the use of 2-iodomelatonin in a dose pro die of 2.5 mg, melatonin, in a dose pro die of 10 mg and 2-bromomelatonin in a dose per day of 3.5 mg, either individually and/or in association with acetyl coenzime A-(AcCoA), in a dose of 8-10 mg per day.

Description: BACKGROUND OF THE INVENTION The present invention relates to a contraceptive and menstrual cycle controlling drug having antikinetosic, oncostatic preventive and therapeutic properties for treating mammary tumours, melanomas and a method therefor. After several years of studies and experiments, related to the mechanism of action of melatonin, this indole is at present considered the most important hormonal product of the pineal gland. The developments in the field of receptor research have led to the localisation of two important receptor sites of melatonin in SNC: the pars tuberalis of the pituitary gland, and the suprachiasmatic nuclei of the hypothalamus. Intensive studies have discovered the biological basis for the mechanism of action of melatonin and its two halogen derivatives (2-bromo and 2-iodomelatonin). Experiments carried out by several researcher groups have confirmed some of the previous discoveries, and have shown that the ability of melatonin to inhibit reproduction, under given experimental conditions, can be related to a direct action of the indole on the hormone responsive elements in the SNC and the pituitary gland. Thus, from prior research it has been known that melatonin can potentially be used as human contraceptive drug. In fact, recently performed research has shown the possibility of using melatonin in association with a progestinic compound (norethisterone), as a powerful contraceptive, which, moreover, provides several advantages such as a low conception risk (less than 1%), lower risk of vascular disturbances (no estrogenic compounds are used) and less painful premenstrual and menstrual periods as well as a less painful premenstrual period (melatonin and agonists thereof are known to have sedative effects). Norethisterone alone, as well as other progestinic derivatives, have been used as contraceptives in the recent years, and they are generally known under the name "minipill". Norethisterone, when used as a "minipill", however has not provided remarkable results in preventing undesired pregnancies (conception risk of about 2.35%). Other progestinic compounds, such as 1-norgestrel, have been found to provide better results, with reduced doses (0.08-0.16 mg). On the other hand, it has been found that melatonin, in order to express its contraceptive action, required comparatively high doses (100-200 mg). The document WO 88/07370 discloses the use of melatonin as a contraceptive possibly in combination with a progestagen. The document EP-A-0 513 702 discloses the use of 2-bromomelatonin as a contraceptive. SUMMARY OF THE INVENTION The main object of the present inventions is to provide a drug which, the drug efficiency being the same, allows the doses to be drastically reduced. Another object of the present invention is that to improve the activity of melatonin, so as to reduce, under like indication and safety conditions, the dose levels thereof. According to one aspect of the present invention, the above mentioned objects, as well as other objects, which will become apparent hereinafter, are achieved by a drug for human use, having contraceptive and menstrual cycle controlling properties, according to claim 1. According to the invention, in order to improve the activity of melatonin and reduce the dose thereof, halogenated derivatives are used, which render agonists with extremely improved qualities in respect to melatonin. In particular, 2-iodomelatonin and 2-bromomelatonin have been used, which have been found to be biologically more active, both in vivo and in vitro, and, more specifically, having an activity of about seven to ten times higher than that of melatonin. It has been found that the use of 2-iodomelatonin and/or 2-bromomelatonin allows to use on the whole a lower amount of the progestinic compound in the combinations. Additionally, the possibility of side effects is further reduced, while providing the above disclosed results. It has been clearly demonstrated that by suspending the long term treatment with melatonin or 2-iodomelatonin or 2-bromomelatonin in association with progestagens (norethisterone, 1-norgestrel, norgestrel, and other), used as contraceptive and menstrual cycle controlling compounds, the fertility of the treated women re-covered to normal levels. With respect to the clinic experimentation, preliminary tests has been carried out on eighty two female patients, having an age between 18 and 40 years, with the following associations of the disclosed substances: a) melatonin and norethisterone with doses per day of respectively 100 mg and 0.50 mg: b) melatonin and 1-norgestrel with doses per day of respectively 100 mg and 0.1 mg: c) 2-iodomelatonin and norethisterone with doses per day of respectively 20 mg and 0.30 mg; d) 2-iodomelatonin and norgestrel with doses per day of respectively 20 mg and 0.5 mg; e) 2-iodomelatonin and 1-norgestrel with doses per day of respectively 30 mg and 0.1 mg: f) 2-bromomelatonin and norethisterone with doses per day of respectively 40 mg and 0.4 mg; g) 2-bromomelatonin and norgestrel with doses per day of respectively 30 mg and 0.5 mg: h) 2-bromomelatonin and 1-norgestrel, with doses per day of respectively 40 mg and 0.1 mg. The use has been mainly made with a contraceptive purpose. After four months of treatment no pregnancy has been recorded, with the exception of a patient at the age of 34, who arbitrarily interrupted for 12 days the administration of the association melatonin-norethisterone. Accordingly, it should be pointed out that the association of 2-iodomelatonin and 2-bromomelatonin with progestinic derivatives (such as norethisterone, 1-norgestrel, norgestrel and other) has shown a contraceptive activity in about 99% of the cases, and that this association allows to use the progestinic compounds in lower amounts, in respect to the amounts required when they are used in other combinations. Moreover, it should be pointed out that by avoiding the use of estrogens, the risk of all side effects, such as vascular problems and steroid dependent neoplasms, is greatly reduced. Moreover, 2-iodomelatonin and 2-bromomelatonin can be used in doses five to ten times lower than those of melatonin. Additionally, the menstrual bleeding period and that preceding the latter are reported less painful, and the recovery of the fertility is obtained by interrupting the administration of the associations herein considered. It should be pointed out that the optimal approach is to administer the drug for 23 days, i.e. the association 2-iodomelatonin or melatonin or 2-bromomelatonin with one of the progestinic derivatives thereof and, for the following five days, the 2-iodomelatonin or 2-bromomelatonin alone. While a possible relationship between the pineal gland (melatonin) and tumour growth and spread has been previously hypothesized, the mode and site of action of this indole and its derivatives are at present still subject of extensive studies. The peripheral blood plasma levels of melatonin were reported altered in patients affected by several neoplasms, and the urinary excretion of the metabolites thereof has been found to be lower in patients affected by similar types neoplasms. Hyperplasia of the pineal gland, which could also indicate an alteration in the production of melatonin, has been observed in patients deceased because of different types of neoplastic diseases. Powerful oncostatic effects of 2-iodomelatonin and 2-bromomelatonin have been observed "in vitro" and "in vivo". In "vitro", the treatment of several human neoplastic cell lines with 2-iodomelatonin and 2-bromomelatonin has caused dose dependant inhibition of the growth (ovarian cell lines SKOV3 and JA, the bladder carcinoma RT112 and the mammary carcinoma MCF-7 cells). In our studies and experiments we have obtained an inhibition greater than 75% of the growth in primary cultures of methastatic nodules of a human malignant melanoma upon treatment "in vitro" with 2-iodomelatonin and 2-bromomelatonin and in primary cultures from different human melanomas, a growth inhibition has been obtained in 6 of 11 patients studied, 2-iodomelatonin and 2-bromomelatonin have also inhibited the growth of the cellular lines MCF-7 in a dose dependent manner, and melatonin has temporarily caused an increase of the estrogen receptor number. The possible influence of 2-iodomelatonin and 2-bromomelatonin on the expression of receptors for other hormones or growth factors has not been clarified yet. Some human malignant melanomas express estrogen receptors and their presence seems to be related to a favourable prognosis. The effect of the treatment 2-iodomelatonin and 2-bromomelatonin "in vivo" and "in vitro" on the expression of the estrogen receptors in malignant melanomas is still subject of extensive studies. The results obtained in our laboratories, however, have demonstrated that 2-iodomelatonin and 2-bromomelatonin cause a reduction both in the number of the lung methastasis and of the local growth of tumours in mice implanted with B-16 melanoma or MS2 fibrosarcoma cells. These data suggest that the inhibition of the neoplastic cellular proliferation by 2-iodomelatonin and 2-bromomelatonin may be due to the binding to a specific receptor. Recently, the expression of a specific and saturable binding of 2-(125I)iodomelatonin has been demonstrated and confirmed in cell cultures, neoplasms and hyperplasias from both humans and laboratory animals. The experimental tests however have shown that while in normal tissues, the binding of 2-iodomelatonin, 2-bromomelatonin and melatonin is of a high affinity, saturable and specific, in neoplastic tissues, the binding affinity is much lower. The long term treatment with melatonin, 2-bromomelatonin and 2-iodomelatonin has contraceptive and menstrual cycle controlling properties and as demonstrated in the human beings, arrest and partial regression of tumours have been observed in some cases, this showing that the three indole derivatives can act as oncostatic agents, in concert with the standard chemotherapy. More recent data have shown that 2-iodomelatonin and 2-bromomelatonin bind to the cellular membranes of some neoplasms such as melanoma, mammary gland cancer, as well as cellular lines immortalized with oncogenic viruses. 2-iodomelatonin and 2-bromomelatonin appear to act both during the progression of the tumour, and during the initiation phase, and may act by suppressing the mitogenic effect of estradiol in estrogen dependent tumours. With respect to the anticinetosic action, it is appropriate to make some preliminary remarks about the action provided by the indole derivatives, related to neurovegetative problems such as those associated with travels by car, sea and air. Melatonin action at the level of the retina has been clearly established. Both, 2-iodomelatonin and 2-bromomelatonin were found to be potent inhibitors of stimulated dopamine release in this organ, very much like melatonin, and are thought to participate in the control of disk shedding and other local adaptive events, related to the speed of perception and visual adjustment. On the other hand, sites of action of melatonin distant from those in the retina may be involved, such as those found in the different parts of the visual pathways, the limbic system, and the cerebellum. In the case of a pineal insufficiency with respect to the synthesis of melatonin, it would be suitable to associate with melatonin, 2-bromomelatonin or 2-idomelatonin, substances adapted to stimulate the endogenous biosynthesis of melatonin such as Acetyl-coenzime A, or "re-uptake" inhibitors of norepinephrine. Accordingly, the association of melatonin or 2-bromomelatonin or 2-iodomelatonin with acetyl CoA not only acts to stimulate the production of melatonin, but also allow for a better performance or the neuroendocrine target structures. All of the details related to the administering, as well as the illustrated doses can be changed depending on the specific patients to be treated without departing from the scope of the invention which is based on the use of 2-iodomelatonin or 2-bromomelatonin in association with one progestagen in the contraceptive therapy and in the menstrual cycle controlling therapy, as well as in the oncostatic preventive therapy of mammary tumours and melanoma, and in the antikinetosic therapy.

Claims: A drug for human use, having a contraceptive and menstrual cycle controlling preventive oncostatic action in mammary tumors and melanomas, and an antikinetosic action, characterized in that said drug comprises an association of 2-iodomelatonin or 2-bromomelatonin and a progestagen. A drug according to Claim 1, characterized in that said drug comprises 2-iodomelatonin and norethisterone, at doses per day of respectively 20-40 mg and 0.30-0.50 mg. A drug according to Claim 1, characterized in that said drug comprises 2-iodomelatonin and norgestrel, at doses per day of respectively 20-40 mg and 0.35-0.80 mg. A drug according to Claim 1, characterized in that said drug comprises 2-iodomelatonin and 1-norgestrel, at doses per day of respectively 20-40 mg and 0.08-0.16 mg. A drug according to Claim 1, characterized in that said drug comprises 2-bromomelatonin and norethisterone, at doses per day of respectively 25-50 mg and 0.30-0.50 mg. A drug according to Claim 1, characterized in that said drug comprises 2-bromomelatonin and 1-norgestrel, at doses per day of respectively 20-40 mg and 0.80-0.16 mg.

Inventors: DI BELLA LUIGI, DURANTI ERMANNO, FRASCHINI FRANCO, LAGUZZI ALDO, STANKOV BOJIDAR, DI BELLA, LUIGI C/O I.F.L.O. S.A.S. DI GIORGIO E, DURANTI, ERMANNO C/O I.F.L.O. S.A.S. DI GIORGIO E, FRASCHINI, FRANCO, LAGUZZI, ALDO C/O I.F.L.O. S.A.S. DI GIORGIO E, STANKOV, BOJIDAR C/O I.F.L.O. S.A.S. DI GIORGIO E, Fraschini, Franco c/o I.F.L.O. S.a.S. di Giorgio e
Applicants: I F L O S A S DI GIORGIO E ALD, I.F.L.O. S.A.S. DI GIORGIO E ALDO LAGUZZI
Application year: 1991
Main classification: A61K31
IPC codes: A61K31, C07D209, A61P13, A61P35, A61P15